Naltrexone: A Cornerstone in Medication-Assisted Treatment for Opioid and Alcohol Dependence
| Product dosage: 50mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $7.16 | $214.86 (0%) | 🛒 Add to cart |
| 60 | $6.78 | $429.72 $406.63 (5%) | 🛒 Add to cart |
| 90 | $6.64
Best per pill | $644.58 $597.39 (7%) | 🛒 Add to cart |
Synonyms | |||
Naltrexone is an opioid antagonist medication primarily indicated for the management of alcohol use disorder and for the blockade of the effects of exogenously administered opioids. It functions by competitively binding to opioid receptors in the brain, thereby preventing other opioid molecules, including both illicit substances and endogenous endorphins in the context of alcohol use, from producing their euphoric and reinforcing effects. This pharmacological action is central to its role in reducing cravings and supporting long-term abstinence as part of a comprehensive treatment plan that includes counseling and psychosocial support. Its availability in both oral and extended-release injectable formulations provides clinicians and patients with flexible dosing options to support adherence and treatment success.
Features
- Pharmacological Class: Pure opioid receptor antagonist.
- Available Formulations: Oral tablets (50 mg standard) and intramuscular extended-release injection (380 mg/vial).
- Mechanism of Action: Competitively binds to mu-opioid receptors, blocking the effects of exogenous opioids and modulating the neurobiological reward pathway associated with alcohol consumption.
- Bioavailability: Oral formulation has 5-40% bioavailability due to significant first-pass metabolism; the injectable formulation provides sustained release over approximately 28 days.
- Metabolism: Primarily hepatic, via dihydrodiol dehydrogenase.
- Elimination Half-life: Oral: approximately 4 hours; Injectable: 5-10 days (based on release rate from depot).
- Scheduling: Not a controlled substance.
Benefits
- Reduces Cravings: Effectively diminishes the intense desire or urge to use opioids or alcohol, a critical factor in preventing relapse.
- Blocks Opioid Effects: Renders the use of opioid drugs non-rewarding, removing the primary incentive for misuse in opioid-dependent individuals.
- Supports Long-Term Abstinence: By disrupting the cycle of reinforcement, it aids in maintaining sobriety and allows patients to engage more effectively in behavioral therapies.
- Flexible Administration Options: The availability of a monthly injectable formulation (Vivitrol®) mitigates challenges with daily adherence and provides continuous receptor coverage.
- Non-Addictive Profile: As an antagonist, naltrexone does not produce euphoria, tolerance, or withdrawal upon discontinuation, eliminating the risk of developing a new substance use disorder.
- Integrates with Comprehensive Care: Serves as a pharmacological cornerstone within a multi-modal treatment approach that addresses the biological, psychological, and social aspects of addiction.
Common use
Naltrexone is FDA-approved for two primary indications. First, it is used for the treatment of alcohol use disorder (AUD) in adults who have already achieved abstinence. It helps maintain abstinence by reducing the craving for alcohol and the perceived “high” or rewarding effects if alcohol is consumed. Second, it is used for the prevention of relapse to opioid dependence following opioid detoxification. It is critical that a patient is fully detoxified and opioid-free before initiating naltrexone therapy to avoid precipitating acute withdrawal. Off-label, it is sometimes used in lower doses (Low-Dose Naltrexone or LDN) for conditions involving immune dysregulation and chronic pain, though robust evidence for these uses is still emerging.
Dosage and direction
For Alcohol Dependence (Oral): The recommended target dose is 50 mg once daily. Some protocols may initiate with 25 mg daily for a few days to assess tolerability before increasing to 50 mg. For Opioid Dependence (Oral): A dose of 50 mg once daily is standard. Initiation must only occur after a patient is completely opioid-free, verified by a negative urine drug screen and the absence of objective and subjective withdrawal signs. A naloxone challenge test may be performed under supervision to confirm the absence of physical dependence. Extended-Release Injectable (Vivitrol®): 380 mg is administered via intramuscular gluteal injection by a healthcare professional every 4 weeks or once monthly. Prior to the first injection, patients must be opioid-free for a minimum of 7-10 days and must be on a stable dose of oral naltrexone to demonstrate tolerability. Administration Note: Oral tablets can be taken with or without food. The injectable formulation requires proper suspension and should not be administered intravenously.
Precautions
- Opioid Abstinence Verification: The most critical precaution is ensuring the patient is free from opioids to prevent precipitated withdrawal, a severe and abrupt onset of withdrawal symptoms.
- Hepatotoxicity: Although rare at recommended doses, dose-related hepatocellular injury is possible. Liver function tests should be obtained at baseline and monitored periodically during therapy, especially in patients with pre-existing liver disease or acute hepatitis.
- Depression and Suicidality: As with many treatments for substance use disorders, patients should be monitored for the emergence or worsening of depression, suicidal thoughts, or unusual changes in behavior.
- Injection Site Reactions: The intramuscular injection can cause pain, tenderness, induration, swelling, erythema, bruising, or pruritus. Proper injection technique is essential to minimize risk.
- Pulmonary Complications: Rare cases of eosinophilic pneumonia and other pulmonary complications have been reported with the injectable formulation.
Contraindications
- Patients receiving opioid analgesics, are currently opioid-dependent, or are in acute opioid withdrawal.
- Patients who have failed the naloxone challenge test or have a positive urine screen for opioids.
- Patients with acute hepatitis or liver failure.
- Known hypersensitivity to naltrexone or any component of the formulation (e.g., polylactide-co-glycolide microspheres in the injectable).
- For the injectable formulation, any patient who has thrombocytopenia or any coagulation disorder (e.g., hemophilia).
Possible side effect
Common side effects are often dose-related and may subside with continued use.
- Nervous System: Insomnia, anxiety, headache, dizziness, nervousness, fatigue.
- Gastrointestinal: Nausea, vomiting, abdominal pain/cramps, diarrhea, constipation, reduced appetite.
- Musculoskeletal: Arthralgia, myalgia, muscle cramps.
- Psychiatric: Depression, irritability.
- Injectable-Specific: Injection site reactions (pain, tenderness, induration, swelling, erythema, bruising, pruritus, nodules).
- Other: Increased thirst, pharyngitis, rhinorrhea, delayed ejaculation.
Serious but rare side effects include hepatotoxicity, suicidal ideation, eosinophilic pneumonia (injectable), and hypersensitivity reactions.
Drug interaction
- Opioid-Containing Medications: Naltrexone will block the therapeutic effects of opioid analgesics (e.g., morphine, oxycodone, hydrocodone), antitussives (e.g., codeine), and antidiarrheals (e.g., diphenoxylate). Attempting to overcome this blockade by taking large doses of opioids can lead to fatal respiratory depression or coma.
- Opioid Agonists/Antagonists: Drugs with mixed agonist-antagonist properties (e.g., buprenorphine, pentazocine, butorphanol, nalbuphine) will have their effects attenuated.
- Medications with Hepatotoxic Potential: Concomitant use of other drugs known to cause hepatic injury (e.g., certain anticonvulsants, antipsychotics, antifungals) may increase the risk of liver toxicity.
- Thioridazine: Naltrexone may increase the somnolence (drowsiness) caused by thioridazine.
Missed dose
- Oral Formulation: If a dose is missed, it should be taken as soon as remembered. If it is close to the time of the next dose, the missed dose should be skipped, and the regular dosing schedule resumed. Patients should not double the dose to make up for a missed one.
- Injectable Formulation: The next injection should be scheduled as soon as possible. A healthcare provider will determine the appropriate scheduling to re-establish the monthly dosing regimen.
Overdose
There is no specific antidote for a naltrexone overdose. Naltrexone itself in large quantities has been associated with dose-related liver toxicity. The primary concern in overdose is the management of symptoms, which may include nausea, vomiting, abdominal pain, dizziness, and lethargy. Supportive care is the mainstay of treatment. In cases where a patient has taken an overdose and is not opioid-dependent, attempting to administer an opioid to reverse symptoms is not effective due to receptor blockade. Hemodialysis is not expected to be beneficial. In the event of an overdose, contact a Poison Control Center immediately.
Storage
- Oral Tablets: Store at controlled room temperature, 20°C to 25°C (68°F to 77°F). Dispense in a tight, light-resistant container. Keep out of reach of children and pets.
- Injectable Formulation (Vivitrol®): The kit must be refrigerated at 2°C to 8°C (36°F to 46°F). It should be kept in the original carton to protect from light. The product can be left at room temperature for no more than 7 days prior to administration. Do not freeze. The product must be administered promptly after suspension.
Disclaimer
This information is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read here. The content has been compiled from various medical resources but may not be exhaustive or reflect the most recent medical developments.
Reviews
- “As an addiction psychiatrist with over 20 years of experience, naltrexone, particularly the extended-release formulation, has been a game-changer for a significant subset of my patients. It provides a crucial ‘buffer’ against relapse while they build coping skills in therapy. The key is proper patient selection and ensuring full detoxification first.” – Dr. A., MD
- “The injectable form’s ability to ensure compliance for a full month is its greatest strength. We see much higher retention rates in our outpatient programs with Vivitrol compared to daily oral medications. The injection site reactions are manageable with proper technique.” – Clinical Nurse Specialist, Addiction Medicine
- “I’ve been on Vivitrol for 18 months after multiple relapses on oral naltrexone. Forgetting a pill was my downfall. Knowing the blockade is active for a full month removes a huge amount of daily anxiety and temptation for me. It gave me the stability I needed to focus on my recovery.” – Patient J.
- “The evidence base for naltrexone in alcohol use disorder is robust. It is underutilized in many primary care settings where it could serve as a highly effective first-line pharmacotherapy. More education for providers is needed.” – Researcher, Public Health
- “While effective, the cost and prior authorization process for the injectable version can be significant barriers to access for many patients who would benefit from it most. We need systems to improve affordability.” – Clinic Director